vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and UGI CORP (UGI). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.1B, roughly 1.4× UGI CORP). UGI CORP runs the higher net margin — 14.4% vs -3.7%, a 18.1% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 3.9%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-155.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -7.5%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
UGI Corporation is a natural gas and electric power distribution company headquartered in King of Prussia, Pennsylvania, with extensive operations in the United States and Europe.
BHC vs UGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.1B |
| Net Profit | $-103.0M | $297.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 22.0% |
| Net Margin | -3.7% | 14.4% |
| Revenue YoY | 9.3% | 3.9% |
| Net Profit YoY | -205.1% | -20.8% |
| EPS (diluted) | $-0.30 | $1.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.1B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.3B | $2.6B | ||
| Q4 24 | $2.6B | $2.0B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.4B | $1.4B | ||
| Q1 24 | $2.2B | $2.4B |
| Q4 25 | $-103.0M | $297.0M | ||
| Q3 25 | $179.0M | $-13.0M | ||
| Q2 25 | $148.0M | $-163.0M | ||
| Q1 25 | $-58.0M | $479.0M | ||
| Q4 24 | $98.0M | $375.0M | ||
| Q3 24 | $-85.0M | $-273.0M | ||
| Q2 24 | $10.0M | $-48.0M | ||
| Q1 24 | $-64.0M | $496.0M |
| Q4 25 | 17.0% | 22.0% | ||
| Q3 25 | 23.1% | 1.1% | ||
| Q2 25 | 17.5% | -6.8% | ||
| Q1 25 | 12.2% | 26.6% | ||
| Q4 24 | 21.8% | 24.5% | ||
| Q3 24 | 12.7% | -20.4% | ||
| Q2 24 | 16.2% | 5.0% | ||
| Q1 24 | 13.1% | 29.7% |
| Q4 25 | -3.7% | 14.4% | ||
| Q3 25 | 6.7% | -1.1% | ||
| Q2 25 | 5.8% | -12.0% | ||
| Q1 25 | -2.6% | 18.2% | ||
| Q4 24 | 3.8% | 18.9% | ||
| Q3 24 | -3.4% | -22.6% | ||
| Q2 24 | 0.4% | -3.6% | ||
| Q1 24 | -3.0% | 20.6% |
| Q4 25 | $-0.30 | $1.34 | ||
| Q3 25 | $0.48 | $-0.08 | ||
| Q2 25 | $0.40 | $-0.76 | ||
| Q1 25 | $-0.16 | $2.19 | ||
| Q4 24 | $0.24 | $1.74 | ||
| Q3 24 | $-0.23 | $-1.26 | ||
| Q2 24 | $0.03 | $-0.23 | ||
| Q1 24 | $-0.17 | $2.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $251.0M |
| Total DebtLower is stronger | $20.8B | $6.0B |
| Stockholders' EquityBook value | $-554.0M | $5.0B |
| Total Assets | $26.4B | $15.8B |
| Debt / EquityLower = less leverage | — | 1.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $251.0M | ||
| Q3 25 | $1.3B | $335.0M | ||
| Q2 25 | $1.7B | $350.0M | ||
| Q1 25 | $1.1B | $426.0M | ||
| Q4 24 | $1.2B | $240.0M | ||
| Q3 24 | $719.0M | $213.0M | ||
| Q2 24 | $595.0M | $183.0M | ||
| Q1 24 | $733.0M | $263.0M |
| Q4 25 | $20.8B | $6.0B | ||
| Q3 25 | $21.0B | $6.5B | ||
| Q2 25 | $21.7B | $5.7B | ||
| Q1 25 | $21.5B | $6.6B | ||
| Q4 24 | $21.6B | $6.6B | ||
| Q3 24 | $21.5B | $6.4B | ||
| Q2 24 | $21.7B | $6.3B | ||
| Q1 24 | $22.1B | $6.7B |
| Q4 25 | $-554.0M | $5.0B | ||
| Q3 25 | $-565.0M | $4.8B | ||
| Q2 25 | $-764.0M | $4.9B | ||
| Q1 25 | $-1.2B | $5.0B | ||
| Q4 24 | $-1.3B | $4.6B | ||
| Q3 24 | $-1.2B | $4.3B | ||
| Q2 24 | $-1.2B | $4.7B | ||
| Q1 24 | $-1.1B | $4.8B |
| Q4 25 | $26.4B | $15.8B | ||
| Q3 25 | $26.8B | $15.5B | ||
| Q2 25 | $27.3B | $15.4B | ||
| Q1 25 | $26.4B | $15.7B | ||
| Q4 24 | $26.5B | $15.4B | ||
| Q3 24 | $26.5B | $15.1B | ||
| Q2 24 | $26.5B | $15.1B | ||
| Q1 24 | $26.9B | $15.6B |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.44× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.34× | ||
| Q1 24 | — | 1.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $66.0M |
| Free Cash FlowOCF − Capex | $403.0M | $-155.0M |
| FCF MarginFCF / Revenue | 14.4% | -7.5% |
| Capex IntensityCapex / Revenue | 3.3% | 10.7% |
| Cash ConversionOCF / Net Profit | — | 0.22× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $282.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $66.0M | ||
| Q3 25 | $405.0M | $90.0M | ||
| Q2 25 | $289.0M | $289.0M | ||
| Q1 25 | $211.0M | $684.0M | ||
| Q4 24 | $601.0M | $164.0M | ||
| Q3 24 | $405.0M | $151.0M | ||
| Q2 24 | $380.0M | $390.0M | ||
| Q1 24 | $211.0M | $522.0M |
| Q4 25 | $403.0M | $-155.0M | ||
| Q3 25 | $314.0M | $-168.0M | ||
| Q2 25 | $190.0M | $67.0M | ||
| Q1 25 | $96.0M | $538.0M | ||
| Q4 24 | $495.0M | $-47.0M | ||
| Q3 24 | $334.0M | $-115.0M | ||
| Q2 24 | $302.0M | $185.0M | ||
| Q1 24 | $129.0M | $353.0M |
| Q4 25 | 14.4% | -7.5% | ||
| Q3 25 | 11.7% | -14.4% | ||
| Q2 25 | 7.5% | 4.9% | ||
| Q1 25 | 4.2% | 20.4% | ||
| Q4 24 | 19.3% | -2.4% | ||
| Q3 24 | 13.3% | -9.5% | ||
| Q2 24 | 12.6% | 13.7% | ||
| Q1 24 | 6.0% | 14.6% |
| Q4 25 | 3.3% | 10.7% | ||
| Q3 25 | 3.4% | 22.1% | ||
| Q2 25 | 3.9% | 16.3% | ||
| Q1 25 | 5.1% | 5.5% | ||
| Q4 24 | 4.1% | 10.6% | ||
| Q3 24 | 2.8% | 22.0% | ||
| Q2 24 | 3.2% | 15.2% | ||
| Q1 24 | 3.8% | 7.0% |
| Q4 25 | — | 0.22× | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 6.13× | 0.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
UGI
Segment breakdown not available.
